**Hygeia Healthcare Holdings Co., Limited**
**海吉亚医疗控股有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 6078)**

# PROFIT WARNING

This announcement is made by Hygeia Healthcare Holdings Co., Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board (the "**Board**") of directors ("**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the six months ended June 30, 2025 and the information currently available to the Board, it is expected that:

(i) the revenue of the Company for the six months ended June 30, 2025 will decrease approximately 15% to 17% as compared to the corresponding period of last year;

(ii) the net profit of the Company for the six months ended June 30, 2025 will decrease approximately 34% to 39% as compared to the corresponding period of last year;

(iii) the non-IFRS adjusted net profit[1] of the Company for the six months ended June 30, 2025 will decrease approximately 32% to 37% as compared to the corresponding period of last year; and

(iv) the net cash generated from operating activities of the Company will increase by approximately 28% to 32% as compared to the corresponding period of last year.

[1] The Group defines "non-IFRS adjusted net profit" as net profit (an IFRS measure) after exclusion of (i) share-based compensation expenses; (ii) depreciation and amortization of the appreciation in valuation of assets arising from acquisitions of hospitals; and (iii) net foreign exchange losses.

Such decrease in revenue, net profit and non-IFRS adjusted net profit of the Group for the six months ended June 30, 2025 was primarily attributable to industry-wide factors such as the centralized procurement and the Diagnosis Related Groups (DRG) payment method reform, the impact of macro-economic headwinds, as well as the impact of increased depreciation and amortization from newly opened hospitals of the Group.

The Group has been proactively responding to such macroeconomic challenges and industry headwinds, maintaining stable operations and preserving its market competitiveness. The Group's trade receivables and total liabilities as of June 30, 2025 are expected to decrease approximately 10% to 11%, and approximately 4.5% to 5.5% respectively, compared to December 31, 2024. The Group's capital expenditure for the six months ended June 30, 2025 is expected to decrease approximately 28% to 29% as compared to the corresponding period of last year, and the Group's free cash flow is expected to achieve significant improvement. Moreover, the Group enhanced the technological capabilities of its hospitals, innovate its business model and strengthen its brand influence in the first half of 2025.

The Group remains steadfast in its mission of "making healthcare services more accessible and affordable and making life healthier (讓醫療更溫暖，讓生命更健康)" and is committed to optimizing its service offerings to meet the diverse healthcare needs of patients and enhance patient satisfaction. The Group remains highly confident in the long-term prospects of the industry and its growth, and continued emphasis will be placed on optimizing its revenue structure, strengthening refined management, improving operational efficiency and enhancing Shareholders' returns.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for the six months ended June 30, 2025, which is expected to be published by the end of August 2025.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
**Hygeia Healthcare Holdings Co., Limited**
**Mr. Zhu Yiwen**
*Chairman*

Hong Kong, August 15, 2025

*As of the date of this announcement, the Board comprises Mr. Zhu Yiwen as chairman and executive Director, Mr. Ren Ai, Ms. Cheng Huanhuan, Mr. Zhang Wenshan and Ms. Jiang Hui as executive Directors, and Mr. Ye Changqing, Mr. Zhao Chun and Mr. Zhang Guozhong as independent non-executive Directors.*